Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.

2021

Uema, Deise

Boegemann, Martin

Krissel, Heiko

Chen, Huanyu

Wagner, Volker Jean

Fizazi, Karim

Gonzalez del Alba, Aranzazu

Mustafa, Ozguroglu

Skoneczna, Iwona Anna